WO2006017688A3 - Combination therapy using transferrin fusion proteins comprising glp-1 - Google Patents
Combination therapy using transferrin fusion proteins comprising glp-1 Download PDFInfo
- Publication number
- WO2006017688A3 WO2006017688A3 PCT/US2005/027800 US2005027800W WO2006017688A3 WO 2006017688 A3 WO2006017688 A3 WO 2006017688A3 US 2005027800 W US2005027800 W US 2005027800W WO 2006017688 A3 WO2006017688 A3 WO 2006017688A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- transferrin fusion
- combination therapy
- glp
- fusion proteins
- inhibitors
- Prior art date
Links
- 102000004338 Transferrin Human genes 0.000 title abstract 3
- 108090000901 Transferrin Proteins 0.000 title abstract 3
- 102000037865 fusion proteins Human genes 0.000 title abstract 3
- 108020001507 fusion proteins Proteins 0.000 title abstract 3
- 239000012581 transferrin Substances 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 102000003729 Neprilysin Human genes 0.000 abstract 2
- 108090000028 Neprilysin Proteins 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 abstract 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Optics & Photonics (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
Abstract
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AP2007003920A AP2007003920A0 (en) | 2004-08-03 | 2005-08-03 | Combination therapy using transferrin fusion proteins comprising glp-1 |
MX2007001424A MX2007001424A (en) | 2004-08-03 | 2005-08-03 | Combination therapy using transferrin fusion proteins comprising glp-1. |
EP05782173A EP1814599A4 (en) | 2004-08-03 | 2005-08-03 | Combination therapy using transferrin fusion proteins comprising glp-1 |
JP2007525008A JP2008509153A (en) | 2004-08-03 | 2005-08-03 | Combination therapy using transferrin fusion protein containing GLP-1 |
AU2005271403A AU2005271403A1 (en) | 2004-08-03 | 2005-08-03 | Combination therapy using transferrin fusion proteins comprising GLP-1 |
BRPI0514115-0A BRPI0514115A (en) | 2004-08-03 | 2005-08-03 | combination therapy employing transferrin fusion proteins comprising glp-1 |
CA002575756A CA2575756A1 (en) | 2004-08-03 | 2005-08-03 | Combination therapy using transferrin fusion proteins comprising glp-1 |
EA200700391A EA200700391A1 (en) | 2004-08-03 | 2005-08-03 | COMBINED TREATMENT WITH THE APPLICATION OF TRANSFERRIN SLIP PROTEINS CONTAINING GLP-1 |
IL181108A IL181108A0 (en) | 2004-08-03 | 2007-02-01 | Combination therapy using transferrin fusion proteins comprising glp-1 |
TNP2007000039A TNSN07039A1 (en) | 2004-08-03 | 2007-02-02 | ASSOCIATION THERAPY USING TRANSFERRIN FUSION PROTEINS COMPRISING GLP-1 |
NO20071018A NO20071018L (en) | 2004-08-03 | 2007-02-22 | Combination treatment using fusion proteins comprising GLP-1 |
GB0703685A GB2431583A (en) | 2004-08-03 | 2007-02-26 | Combination therapy using transferrin fusion proteins comprising GLP-1 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59803104P | 2004-08-03 | 2004-08-03 | |
US60/598,031 | 2004-08-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006017688A2 WO2006017688A2 (en) | 2006-02-16 |
WO2006017688A3 true WO2006017688A3 (en) | 2006-08-03 |
Family
ID=35839920
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/027800 WO2006017688A2 (en) | 2004-08-03 | 2005-08-03 | Combination therapy using transferrin fusion proteins comprising glp-1 |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP1814599A4 (en) |
JP (1) | JP2008509153A (en) |
KR (1) | KR20070085224A (en) |
CN (1) | CN101035568A (en) |
AP (1) | AP2007003920A0 (en) |
AU (1) | AU2005271403A1 (en) |
BR (1) | BRPI0514115A (en) |
CA (1) | CA2575756A1 (en) |
CR (1) | CR8954A (en) |
EA (1) | EA200700391A1 (en) |
GB (1) | GB2431583A (en) |
IL (1) | IL181108A0 (en) |
MA (1) | MA28843B1 (en) |
MX (1) | MX2007001424A (en) |
NO (1) | NO20071018L (en) |
RU (1) | RU2007107808A (en) |
TN (1) | TNSN07039A1 (en) |
WO (1) | WO2006017688A2 (en) |
ZA (1) | ZA200701484B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9220687B2 (en) | 2008-12-29 | 2015-12-29 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
US8129504B2 (en) | 2001-08-30 | 2012-03-06 | Biorexis Technology, Inc. | Oral delivery of modified transferrin fusion proteins |
EP1494732B1 (en) | 2002-03-20 | 2008-01-30 | MannKind Corporation | Inhalation apparatus |
KR101273120B1 (en) | 2004-08-20 | 2013-06-13 | 맨카인드 코포레이션 | Catalysis of diketopiperazine synthesis |
KR20130066695A (en) | 2004-08-23 | 2013-06-20 | 맨카인드 코포레이션 | Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery |
EP1858546A4 (en) * | 2005-03-04 | 2009-03-04 | Biorexis Pharmaceutical Corp | Modified transferrin fusion proteins |
IN2014DN09128A (en) | 2005-09-14 | 2015-07-10 | Mannkind Corp | |
BRPI0707991B8 (en) | 2006-02-22 | 2021-05-25 | Mannkind Corp | methods of preparing a dry powder medicine with an improved pharmaceutical property, said dry powder and using an effective amount of the dry powder |
CN101432025B (en) * | 2006-03-21 | 2012-04-04 | 安米林药品公司 | Peptide-peptidase inhibitor conjugates and methods of using same |
WO2008012629A2 (en) * | 2006-07-24 | 2008-01-31 | Biorexis Pharmaceutical Corporation | Exendin fusion proteins |
WO2008033395A2 (en) * | 2006-09-14 | 2008-03-20 | Biorexis Pharmaceutical Corporation | Melanocortin and transferrin fusion proteins |
US8598314B2 (en) | 2007-09-27 | 2013-12-03 | Amylin Pharmaceuticals, Llc | Peptide-peptidase-inhibitor conjugates and methods of making and using same |
CN109568740B (en) | 2008-06-13 | 2022-05-27 | 曼金德公司 | Dry powder inhaler and system for drug delivery |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
ES2904623T3 (en) | 2008-06-20 | 2022-04-05 | Mannkind Corp | Interactive device to establish a real-time profile of inhalation efforts |
TWI494123B (en) | 2008-08-11 | 2015-08-01 | Mannkind Corp | Use of ultrarapid acting insulin |
PL2405963T3 (en) | 2009-03-11 | 2014-04-30 | Mannkind Corp | Apparatus, system and method for measuring resistance of an inhaler |
KR101875969B1 (en) | 2009-06-12 | 2018-07-06 | 맨카인드 코포레이션 | Diketopiperazine microparticles with defined specific surface areas |
EP2496295A1 (en) | 2009-11-03 | 2012-09-12 | MannKind Corporation | An apparatus and method for simulating inhalation efforts |
KR20130117755A (en) | 2010-06-21 | 2013-10-28 | 맨카인드 코포레이션 | Dry powder drug delivery system and methods |
WO2012026526A1 (en) * | 2010-08-27 | 2012-03-01 | 国立大学法人宮崎大学 | Hemokinin-1 receptor and hemokinin-1-derived peptide |
JP6133270B2 (en) | 2011-04-01 | 2017-05-24 | マンカインド コーポレイション | Blister packaging for drug cartridge |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
RU2477726C1 (en) * | 2011-10-18 | 2013-03-20 | Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") | Substituted phenoxyacetic acids, their esters and amides containing 2,6-dioxo-2,3,6,7-tetrahydro-1h-pyrin-8-yl fragments - a2a adenosine receptor antagonists and use thereof |
BR112014009686A2 (en) | 2011-10-24 | 2018-08-07 | Mannkind Corp | Inhalable analgesic composition, dry powder and method for treating pain |
CN103160565A (en) * | 2011-12-09 | 2013-06-19 | 彩虹天健康科技研究(北京)有限责任公司 | Research for influence on endocytosis of cell transferrins of UNC-51 kinase |
WO2013162050A1 (en) * | 2012-04-23 | 2013-10-31 | 株式会社Nrlファーマ | Lactoferrin fusion protein and method for producing same |
AU2013289957B2 (en) | 2012-07-12 | 2017-02-23 | Mannkind Corporation | Dry powder drug delivery systems and methods |
UA116217C2 (en) | 2012-10-09 | 2018-02-26 | Санофі | Exendin-4 derivatives as dual glp1/glucagon agonists |
EP2911690A1 (en) | 2012-10-26 | 2015-09-02 | MannKind Corporation | Inhalable influenza vaccine compositions and methods |
RU2652783C2 (en) | 2012-12-21 | 2018-05-03 | Санофи | Dual glp1/gip or trigonal glp1/gip/glucagon agonists |
ES2754388T3 (en) | 2013-03-15 | 2020-04-17 | Mannkind Corp | Compositions and methods of microcrystalline dicetopiperazine |
CN103275177B (en) * | 2013-06-24 | 2015-08-12 | 南京财经大学 | There is the little peptide of feritin and ACE dual restraining activities, its preparation method and application |
BR122019026637B1 (en) | 2013-07-18 | 2023-09-26 | Mannkind Corporation | PHARMACEUTICAL DRY POWDER FORMULATIONS AND METHOD FOR MANUFACTURING A DRY POWDER FORMULATION |
WO2015021064A1 (en) | 2013-08-05 | 2015-02-12 | Mannkind Corporation | Insufflation apparatus and methods |
WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
TW201609797A (en) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | Dual GLP-1/glucagon receptor agonists |
TW201609796A (en) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | Non-acylated EXENDIN-4 peptide analogues |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
TW201625668A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists |
TW201625670A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4 |
TW201625669A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
US20160130324A1 (en) * | 2014-10-31 | 2016-05-12 | Shire Human Genetic Therapies, Inc. | C1 Inhibitor Fusion Proteins and Uses Thereof |
CN104645317B (en) * | 2015-01-28 | 2020-04-17 | 中国科学院天津工业生物技术研究所 | Application of polypeptide compound as polypeptide or protein drug carrier, method and fusion protein compound thereof |
AR105319A1 (en) | 2015-06-05 | 2017-09-27 | Sanofi Sa | PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR |
TW201706291A (en) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists |
CA3080406A1 (en) | 2016-10-28 | 2018-05-03 | Nrl Pharma, Inc. | Lactoferrin/albumin fusion protein and production method thereof |
US11459368B2 (en) | 2017-07-14 | 2022-10-04 | Livactus, Inc. | Insulin-transferrin fusion protein and its prodrug, proinsulin-transferrin, for overcoming insulin resistance |
WO2019243502A1 (en) * | 2018-06-21 | 2019-12-26 | Novo Nordisk A/S | Novel compounds for treatment of obesity |
CN110218259B (en) * | 2019-06-24 | 2022-09-16 | 王跃驹 | Application of fusion protein of glucagon-like peptide-1 short peptide and transferrin produced by plants in preparing oral hypoglycemic capsules |
CN112661862B (en) * | 2020-12-25 | 2023-03-31 | 深圳大学 | Fusion protein and preparation method and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5925351A (en) * | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
US20020156036A1 (en) * | 2000-09-06 | 2002-10-24 | Nicolau Yves Claude | Methods and compositions for diseases associated with amyloidosis |
US20030138404A1 (en) * | 1995-07-14 | 2003-07-24 | Meiogen Biotechnology Corporation | Interferon antagonists useful for the treatment of interferon related diseases |
US20030221201A1 (en) * | 2001-08-30 | 2003-11-27 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
WO2004019872A2 (en) * | 2002-08-30 | 2004-03-11 | Biorexis Pharmaceutical Corporation | Oral delivery of modified transferrin fusion proteins |
AU2003201274A1 (en) * | 2002-01-11 | 2003-07-24 | Novo Nordisk A/S | Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes |
ES2347144T3 (en) * | 2002-08-30 | 2010-10-26 | Biorexis Pharmaceutical Corporation | FUSION PROTEINS OF THE MODIFIED TRANSFERRINE THAT INCLUDE DOMINOS AINO OR CARBOXILO OF TRANSFERRINA DUPLICATED. |
-
2005
- 2005-08-03 WO PCT/US2005/027800 patent/WO2006017688A2/en active Application Filing
- 2005-08-03 MX MX2007001424A patent/MX2007001424A/en not_active Application Discontinuation
- 2005-08-03 KR KR1020077005257A patent/KR20070085224A/en not_active Application Discontinuation
- 2005-08-03 JP JP2007525008A patent/JP2008509153A/en not_active Withdrawn
- 2005-08-03 CA CA002575756A patent/CA2575756A1/en not_active Abandoned
- 2005-08-03 ZA ZA200701484A patent/ZA200701484B/en unknown
- 2005-08-03 RU RU2007107808/14A patent/RU2007107808A/en not_active Application Discontinuation
- 2005-08-03 BR BRPI0514115-0A patent/BRPI0514115A/en not_active IP Right Cessation
- 2005-08-03 EP EP05782173A patent/EP1814599A4/en not_active Withdrawn
- 2005-08-03 AP AP2007003920A patent/AP2007003920A0/en unknown
- 2005-08-03 EA EA200700391A patent/EA200700391A1/en unknown
- 2005-08-03 CN CNA2005800336740A patent/CN101035568A/en active Pending
- 2005-08-03 AU AU2005271403A patent/AU2005271403A1/en not_active Abandoned
-
2007
- 2007-02-01 IL IL181108A patent/IL181108A0/en unknown
- 2007-02-02 TN TNP2007000039A patent/TNSN07039A1/en unknown
- 2007-02-22 NO NO20071018A patent/NO20071018L/en not_active Application Discontinuation
- 2007-02-26 GB GB0703685A patent/GB2431583A/en not_active Withdrawn
- 2007-03-02 MA MA29727A patent/MA28843B1/en unknown
- 2007-03-02 CR CR8954A patent/CR8954A/en not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030138404A1 (en) * | 1995-07-14 | 2003-07-24 | Meiogen Biotechnology Corporation | Interferon antagonists useful for the treatment of interferon related diseases |
US5925351A (en) * | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
US20020156036A1 (en) * | 2000-09-06 | 2002-10-24 | Nicolau Yves Claude | Methods and compositions for diseases associated with amyloidosis |
US20030221201A1 (en) * | 2001-08-30 | 2003-11-27 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9220687B2 (en) | 2008-12-29 | 2015-12-29 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
Also Published As
Publication number | Publication date |
---|---|
CN101035568A (en) | 2007-09-12 |
WO2006017688A2 (en) | 2006-02-16 |
AP2007003920A0 (en) | 2007-02-28 |
RU2007107808A (en) | 2008-09-10 |
EA200700391A1 (en) | 2007-10-26 |
EP1814599A4 (en) | 2008-12-17 |
JP2008509153A (en) | 2008-03-27 |
KR20070085224A (en) | 2007-08-27 |
EP1814599A2 (en) | 2007-08-08 |
NO20071018L (en) | 2007-04-11 |
MX2007001424A (en) | 2008-03-13 |
GB0703685D0 (en) | 2007-04-04 |
AU2005271403A1 (en) | 2006-02-16 |
BRPI0514115A (en) | 2008-05-27 |
ZA200701484B (en) | 2008-07-30 |
GB2431583A (en) | 2007-05-02 |
MA28843B1 (en) | 2007-09-03 |
CR8954A (en) | 2007-10-02 |
TNSN07039A1 (en) | 2008-06-02 |
CA2575756A1 (en) | 2006-02-16 |
IL181108A0 (en) | 2007-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006017688A3 (en) | Combination therapy using transferrin fusion proteins comprising glp-1 | |
GEP20105111B (en) | Rage fusion proteins and methods of use | |
WO2004078777A3 (en) | Dipeptidyl-peptidase protected proteins | |
WO2005067601A3 (en) | Vectors for recombinant protein expression in e.coli | |
WO2005046709A3 (en) | Tgf - beta binding and supported peptides | |
WO2005047327A8 (en) | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO | |
WO2007091250A3 (en) | Enzyme replacement therapy for treating lysosomal storage diseases | |
IL177049A (en) | HETERODIMERIC FOLLICLE STIMULATING HORMONE - Fc (FSH-Fc) FUSION PROTEINS FOR THE TREATMENT OF INFERTILITY | |
WO2006041641A3 (en) | Therapeutic agents with decreased toxicity | |
WO2006023359A3 (en) | Selective vpac2 receptor peptide agonists | |
WO2008033395A3 (en) | Melanocortin and transferrin fusion proteins | |
WO2004074486A3 (en) | Fusion proteins of interferon alpha muteins with improved properties | |
WO2008040190A8 (en) | Small peptides for anti-angiogenesis and use thereof | |
WO2008060634A3 (en) | Human complement c3 derivatives with cobra venom factor-like function | |
WO2005051902A3 (en) | Modified mscl protein channel | |
WO2005059131A3 (en) | Protein binding miniature proteins and uses thereof | |
EP2096120A3 (en) | Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome | |
WO2007018879A3 (en) | Interferon-gamma antagonists and therapeutic uses thereof | |
WO2007143161A3 (en) | Use of proteins and peptides of the tgf-beta superfamily for purification and therapeutic methods | |
WO2001007479A3 (en) | Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases | |
WO2006138610A3 (en) | Interferon-alpha/beta binding fusion proteins and therapeutic uses thereof | |
WO2005000891A3 (en) | Thrombopoietin proteins with improved properties | |
WO2007002739A3 (en) | Chromium-amino acid complexes in the treatment of diabetes and other diseases | |
WO2004113386A3 (en) | Modified hirudin proteins and t-cell epitopes in hirudin | |
WO2002079222A3 (en) | Fusion proteins for specific treatment of cancer and auto-immune diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2575756 Country of ref document: CA Ref document number: 2005271403 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 181108 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/001424 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: DZP2007000092 Country of ref document: DZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007525008 Country of ref document: JP Ref document number: 12007500315 Country of ref document: PH |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: AP/P/2007/003920 Country of ref document: AP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007/01484 Country of ref document: ZA Ref document number: 200701484 Country of ref document: ZA |
|
ENP | Entry into the national phase |
Ref document number: 2005271403 Country of ref document: AU Date of ref document: 20050803 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005271403 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 0703685 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20050803 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 0703685.8 Country of ref document: GB |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005782173 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 553501 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 760/KOLNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 9906 Country of ref document: GE Ref document number: 07021337 Country of ref document: CO Ref document number: 1200700477 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007107808 Country of ref document: RU Ref document number: 1020077005257 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200700391 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580033674.0 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005782173 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0514115 Country of ref document: BR |